KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Inventory (2016 - 2025)

Jazz Pharmaceuticals has reported Inventory over the past 16 years, most recently at $417.0 million for Q4 2025.

  • Quarterly results put Inventory at $417.0 million for Q4 2025, down 13.21% from a year ago — trailing twelve months through Dec 2025 was $417.0 million (down 13.21% YoY), and the annual figure for FY2025 was $417.0 million, down 13.21%.
  • Inventory for Q4 2025 was $417.0 million at Jazz Pharmaceuticals, down from $483.1 million in the prior quarter.
  • Over the last five years, Inventory for JAZZ hit a ceiling of $1.3 billion in Q2 2021 and a floor of $115.5 million in Q1 2021.
  • Median Inventory over the past 5 years was $604.4 million (2023), compared with a mean of $672.2 million.
  • Biggest five-year swings in Inventory: soared 1252.22% in 2021 and later plummeted 36.01% in 2022.
  • Jazz Pharmaceuticals' Inventory stood at $1.1 billion in 2021, then tumbled by 33.43% to $714.1 million in 2022, then decreased by 16.39% to $597.0 million in 2023, then dropped by 19.53% to $480.4 million in 2024, then dropped by 13.21% to $417.0 million in 2025.
  • The last three reported values for Inventory were $417.0 million (Q4 2025), $483.1 million (Q3 2025), and $505.0 million (Q2 2025) per Business Quant data.